University of Texas System

Trizell Limited

Colin P Dinney

Yan E Wang

David J McConkey

Bogdan A Czerniak

Ashish M Kamat

Joseph Briggman

Diana Urbauer

Liana Adam

Keith Baggerly

Tadeusz Majewski

Shizhen Zhang

Jolanta Bondaruk

A method of treating bladder cancer comprising diagnosing bladder cancer in a human, measuring the human's level of CDKN2A expression, and then instilling into the human an agent which induces interferon expression.

CDKN2A companion diagnostic for bladder cancer interferon therapy

The present disclosure provides methods and compositions for the detection of bladder in a subject using four locus-specific probes to 6p22, 8q22, 11q13, and 20p11.2.

Multi-color fish test for bladder cancer detection

Methods for predicting cancer recurrence following a BCG immunotherapy are provided. In some aspects, cytokine levels from a patient are measured before and after a BCG therapy and the changes in cytokine levels are used to determine the risk of cancer lapse. Methods for selecting a patient for a further anti-cancer therapy are also provided.

Use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer

In some embodiments, the present invention provides methods for enhancing the sensitivity of cancer cells to anti-EGFR treatment, wherein the method comprises the introduction of a miR-200 miRNA to the cancer cells. In other embodiments, the present invention provides methods for treating cancer by exposing the cancer cells to an anti-EGFR composition after the above-mentioned enhancement step. In other embodiments, the present invention provides methods for assessing and enhancing the sensitivity of cancer cells to anti-EGFR treatment. In various other embodiments, the present invention provides compositions and expression vectors for practicing the afore-mentioned methods.

Methods and compositions for anti-EGFR treatment

Growing community of inventors

Houston, TX, United States of America

Colin P Dinney